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Azole resistance in Aspergillus fumigatus is an emerging public health concern. Recently, a novel fungicide-driven mutation in
the cyp51A gene and its promoter, TR46/Y121F/T289A, leading to high-level resistance to voriconazole has been identified in The
Netherlands, Belgium, Germany, Denmark, Tanzania, and India in both clinical and environmental samples. Here we report the
first description of A. fumigatus carrying this mutation in France, in a cystic fibrosis patient, underlining the need for extensive
monitoring of Aspergillus resistance.
Azole-resistant Aspergillus fumigatus isolates have been in-creasingly reported in Europe since the later years of the first
decade of the 2000s. This emerging public health concern occurs
through two distinct routes of acquisition: in vivo selection of
resistance as a consequence of long-term azole treatment and de
novo acquisition of a resistant isolate directly from the environ-
ment, linked to the widespread use of azole fungicides in agricul-
ture. Besides the TR34/L98H mutation in the cyp51A gene first
described in TheNetherlands, a novel fungicide-drivenmutation,
TR46/Y121F/T289A, has been recently identified. Until now, the
TR46/Y121F/T289A mutation has been reported in both environ-
mental and clinical samples in four countries across Europe (1–7),
in Asia (8), and, more recently, in Africa (9), suggesting a large
geographical spread. Here we provide the first description of A.
fumigatus carrying a TR46/Y121F/T289A mutation in a cystic fi-
brosis patient in France.
A 23-year-old male cystic fibrosis patient with follow-up at the
Pneumology Department at Rouen University Hospital, France,
was seen in consultation in March 2014. This patient had high
levels of total IgE and Aspergillus-specific IgE with positive Asper-
gillus-specific IgG antibodies, suggesting a diagnosis of allergic
bronchopulmonary aspergillosis. He had a history ofA. fumigatus
airway colonization and exposure tomold-active azoles (itracona-
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TABLE 1 Overview of the characteristics of all Aspergillus fumigatus strains isolated from sputum samples of the patient
Strain
no.
Reference in the
dendrogram Mo/yr of isolation
MIC (mg/liter) (EUCAST)a
cyp51A mutationsITC VRC
1 14-105-2468 March 2014 8 8 TR46/Y121F/T289A
2 14-148-2457 November 2013 0.5 0.5 Wild type
3 14-148-2460 February 2013 8 8 TR46/Y121F/T289A
4 141428-459 January 2013 0.5 1 Wild type
5 14-148-2458 January 2013 0.25 0.25 Wild type
6 14-148-2456 December 2010 Not determined Not determined F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C
7 14-148-2455 September 2010 Not determined Not determined F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C
8 14-148-2454 July 2010 Not determined Not determined F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C
9 None July 2009 Not determined Not determined F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C
10 14-148-2450 July 2009 0.25 1 Wild type
11 14-148-2448 March 2009 0.25 1 Wild type
12 14-148-2447 December 2007 0.25 1 Wild type
13 14-148-2445 May 2007 0.5 2 Wild type
14 None February 2007 0.5 1 F46Y, G89G, M172V, N248T, D255E, L358L, E427K, C454C
a ITC, itraconazole; VRC, voriconazole.
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zole and voriconazole) since 2002. At the time of the consultation,
he was treated with voriconazole.Mycological cultures of the spu-
tum collected during the consultation grew A. fumigatus (strain
1). Species identification was obtained by both macroscopic and
microscopic characteristics on Sabouraud’s agar medium to-
gether with sequencing of the beta-tubulin gene (10). In accor-
dance with a local research protocol aiming at the surveillance of
azole resistance, this isolate was tested for antifungal susceptibility
by the Etest method (bioMérieux, Marcy l’Etoile, France). Unex-
pectedly, this strain exhibited high-level resistance to voriconazole
(MIC32 g/ml) in comparison with itraconazole (MIC 8
g/ml) and posaconazole (MIC 1 g/ml). Antifungal suscepti-
bility was confirmed by the EUCAST broth microdilution refer-
ence method (Table 1) (11, 12). Nucleotide sequencing of the
cyp51A gene and its promoter, using previously described primers
(13, 14) and in-house-designed primers (CYP51AF-F1 [5=-ATTT
CCCTCATCACTGCAA], CYP51AF-R1 [5=-CATCATGTGCGC
AATCTCTT], CYP51AF-F2 [5=-AGAAGCGAGATGCTGCTC
AT], and CYP51AF-R2 [5=-CCTTTGAAGTCCTCGATGGT]),
showed the TR46/Y121F/T289Amutation. Antifungal therapywas
therefore switched to posaconazole in April 2014 and then to
caspofungin (50 mg per day) in July 2014 because of pulmonary
exacerbation.
Given these findings, we retrospectively analyzed allA. fumigatus
strains that had been isolated from this patient since 2007 (n 13)
for itraconazole and voriconazole susceptibility, cyp51A sequenc-
ing, and microsatellite genotyping. As shown in Table 1, our pa-
tient had already been colonized by a TR46/Y121F/T289A isolate 1
year before, in February 2013 (strain 3). All remaining isolates
collected before February 2013were azole susceptible, either being
wild type for the cyp51A gene or carrying mutations previously
found in both azole-resistant and azole-susceptible isolates (15).
As only a single colony was subjected to in vitro susceptibility
testing, other azole-resistant isolates could have been missed. Mi-
crosatellite genotyping was performed using a panel of nine short
tandem repeats as described previously (16). As illustrated in Ta-
ble 1, both TR46/Y121F/T289A isolates from our patient had the
same genotype as a strain previously isolated in Germany (7) (Ta-
ble 1). To gain further insights into the route of acquisition of this
azole-resistant isolate in our patient, we conducted an environ-
mental study by performing soil samplings next to the patient’s
home as described previously (17), as well as surface samplings
(contact agar plates) in his office. Neither A. fumigatus carrying
TR46/Y121F/T289A nor A. fumigatus carrying TR34/L98H was
identified.
Aspergillus fumigatus isolates carrying the TR46/Y121F/T289A
mutation were first described in December 2009 in The Nether-
lands (2). Since then, such isolates have been evidenced in three
other European countries, namely, Belgium (1, 5), Germany (3,
7), and Denmark (4), and recently in India (8) and Tanzania (9)
(Table 2 and Fig. 1). Taken together, these findings suggest, as dis-
cussed previously for TR34/L98H isolates, a large geographical spread
of this resistance mechanism. Several lines of evidence indicate that,
as in the case of TR34/L98H, TR46/Y121F/T289A has emerged
through a fungicide-driven route (18), such isolates being found in
both azole-naive patients (1, 2, 6, 7) and azole-exposed patients (2, 3,
FIG 1 Geographical spread of the TR46/Y121F/T289A resistance mechanism (for each strain, the exact location and origin [clinical or environmental] are
indicated). Map data: Google GeoBasis-DE/BKG and Google, INEGI.
TR46-Resistant Aspergillus fumigatus in France
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5, 7) as well as in samples from the environment (2, 8, 9). Here we
report thefirstdescriptionofA. fumigatus carrying theTR46/Y121F/
T289A mutation isolated from a French patient.
Interestingly, our patient organized trips to The Nether-
lands as a tour operator. For these working purposes, he trav-
eled to Amsterdam in November 2012, 3 months before the
first isolation of the TR46/Y121F/T289A strain from his sputum
(February 2013). Moreover, he regularly received advertising
postal packages from Dutch flower producers which were
opened in his office. Three hypotheses can explain the route of
acquisition of this TR46/Y121F/T289A strain in our patient. (i)
The first hypothesis is that he inhaled spores carrying TR46/
Y121F/T289A during his trip to The Netherlands (2). (ii) The
second hypothesis is that colonization occurred after he in-
haled spores carrying TR46/Y121F/T289A from his environ-
ment in France. Our environmental study conducted next to
the patient’s home, less than 100 km from Belgium (where
TR46/Y121F/T289A strains have been recently identified [1]),
failed to detect TR46/Y121F/T289A environmental isolates.
Nevertheless, environmental isolates carrying this mutation
have been recently identified by our team in the same region in
France, supporting this hypothesis (unpublished data). (iii)
The last hypothesis is that colonization occurred after he in-
haled A. fumigatus spores carrying TR46/Y121F/T289A that had
escaped while he was opening the packages received from The
Netherlands. Though the French strains are genetically indistin-
guishable from the German isolates and genetically different from
theDutch isolates (Fig. 2), the route of acquisition in our patient is
unclear, as the spores probably followed an airborne migration
pattern as hypothesized previously for TR34/L98H (19, 20).
The present report provides evidence that A. fumigatus vori-
conazole-resistant isolates carrying the TR46/Y121F/T289Amuta-
tion can be now isolated from clinical samples in France. As ob-
served with TR34/L98H, a geographical spread of this resistance
mechanism is ongoing across Europe and possibly worldwide.
These findings, together with the high-level voriconazole resis-
tance of the TR46/Y121F/T289A strains both in vitro and in vivo (1,
2, 4–6), underline the need for intensive investigations to deter-
mine the prevalence of the mutation in both clinical and environ-
mental samples. In line with this, as recommended by a European
Centre for Disease Prevention and Control (ECDC) technical re-
port (18), antifungal susceptibility testing of triazoles should be
performed on all clinical A. fumigatus isolates before starting
antifungal therapy.
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FIG 2 STRAf dendrogram highlighting the genetic relatedness between the Aspergillus fumigatus isolate collected from our patient and previously reported
TR46/Y121F/T289A isolates.
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